CareDX (CDNA) in Pivotal Point Check: New 52-Week High After Earnings Fireworks, Medicare Reimbursement Breakthrough, and Forecast Increase!
Reading Time: 2 minutes
Strong Q2 Growth: Revenue increase of 52% to 132 million USD significantly exceeds analyst estimates. Convincing Profitability: Adjusted earnings per share of 0.37 USD are driven by increasing test volumes in transplantation diagnostics. Optimistic Outlook: Annual revenue forecast raised to up to 500 million USD. CareDx, known for precision medicine and diagnostics focused on transplantation monitoring and oncology, caused a significant boost on the stock market on July 31. The stock climbed noticeably following the release of the Q2...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
